Medicare Diagnostic Radiopharmaceutical Payment Equity Act

Recipients

Your Representative

Contact

*Required fields

* Title:

* First Name:

* Last Name:

* Email Address:

* Address 1:

Address 2:

* City:

* State/Province:

* ZIP/Postal Code:

* Phone Number:

Yes, I'd like to receive email updates from the Lymphoma Research Foundation.

Remember me. What's this?

Message

* Subject:

Dear [Decision Maker],

As your constituent and someone who has been personally affected by lymphoma, the most common form of blood cancer, I am writing today regarding diagnostic radiopharmaceuticals, which necessary for all nuclear medicine imaging studies to diagnose and determine the severity of disease. Nuclear medicine and molecular imaging are unique imaging modalities that evaluate function of one or more organs. In many disease processes, the functional changes precede or are more pronounced than structural changes seen with modalities such as CT or MRI. As a result, physicians are able to offer more effective management or treatment plans in a timely fashion to their patients suffering from conditions such as Alzheimer's, Parkinson's disease, cardiovascular conditions, various types of cancers, and other maladies.

* Personalize your message

I am asking that you consider being a cosponsor of HR 3772; and I thank you and your staff for your consideration and dedication to this important issue.

Sincerely,
[Your Name]
[Your Address]
[City, State ZIP]
[Your Email]